• Price (USD)23.84
  • Today's Change0.435 / 1.86%
  • Shares traded17.67k
  • 1 Year change-7.27%
  • Beta--
Data delayed at least 15 minutes, as of Jun 02 2023 20:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SHL:ASX since
Medical Laboratories DuesseldorfAnnounced26 Apr 202326 Apr 2023Announced-1.54%197.50m
Diagnosticum - PartG der Fachaerzte fuer Labormedizin der Fachaerzte fuer Mikrobiologie der Fachaerzte fuer Pathologie der Fachaerzte fuer Humangenetik Dr Scholz und PartnerAnnounced02 Apr 202302 Apr 2023Announced2.78%205.94m
Data delayed at least 20 minutes, as of Jun 02 2023 07:10 BST.

Institutional shareholders

0.32%Per cent of shares held by top holders
HolderShares% Held
Cullen Capital Management LLCas of 31 Mar 20231.46m0.31%
Boston Common Asset Management LLCas of 31 Mar 202323.33k0.01%
Envestnet Asset Management, Inc.as of 28 Feb 20235.33k0.00%
Boston Partners Global Investors, Inc.as of 28 Feb 20233.35k0.00%
PNC Investments LLCas of 31 Mar 20231.17k0.00%
Front Row Advisors LLCas of 31 Mar 2023484.000.00%
Cornerstone Planning Group LLCas of 31 Dec 2022214.000.00%
Financial Gravity Asset Management, Inc.as of 31 Mar 202324.000.00%
First Horizon Advisors, Inc.as of 31 Mar 202315.000.00%
Ativo Capital Management LLCas of 31 Mar 20230.000.00%
More ▼
Data from 31 Dec 2022 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.